EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Comparing cefazolin/metronidazole, piperacillin‐tazobactam, or cefoxitin as surgical antibiotic prophylaxis in patients undergoing pancreaticoduodenectomy: A retrospective cohort study

Lily J Park, Daniel D'Souza, Tania Kazi, Felipe Rodriguez, Christopher Griffiths, Tyler McKechnie, Dominik Mertz, Pablo E Serrano

Journal of Surgical Oncology · 2024

DOI: 10.1002/jso.27641 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Lily J Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of General Surgery, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Pancreaticoduodenectomy, Surgical Wound Infection, Metronidazole, Antibiotic Prophylaxis. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preoperative antibiotic options for pancreaticoduodenectomy (PD) include cefoxitin (CX), piperacillin‐tazobactam (PT), or combined cefazolin and metronidazole (CM). Recent studies suggest the superiority of PT over CX, but evidence for CM is unclear.

Objective

To explore the impact of preoperative antibiotic selection (CM vs. PT and CX vs. PT) on the development of surgical site infections (SSI).

Methods

Consecutive adult patients at one institution who underwent PD from November 2017 to December 2021 and received either CM, PT, or CX preoperatively, were included. The primary outcome was SSI. Secondary outcomes included postoperative infections and clinically significant postoperative pancreatic fistula (POPF). Logistic regression models were used.

Results

Among 127 patients included in the study, PT, CM, and CX were administered in 46 (36.2%), 44 (34.6%), and 37 (29.4%) patients, respectively. There were 32 (27.1%) SSI, 20 (36.1%) infections, and 21 (22.9%) POPF events. PT use was associated with reduced risk of SSI compared to CX (OR: 0.32, 95% CI: 0.11−0.89, p = 0.03), but there was no difference as compared to CM (OR: 0.75, 95% CI: 0.27−2.13, p = 0.59). There were no differences in secondary outcomes.

Conclusion

PT reduced SSI rates compared to CX but was no different to CM among patients undergoing PD at our center.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PancreaticoduodenectomySurgical Wound InfectionMetronidazoleAntibiotic ProphylaxisAnti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationCefazolinHumansMaleFemaleRetrospective StudiesAgedMiddle AgedCefoxitinPancreatic NeoplasmsFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

antibacterial agentsantibiotic prophylaxispancreaticoduodenectomysurgical wound infection

Substanzen

MetronidazoleAnti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationCefazolinCefoxitin

Autor:innen und Institutionen

  • Department of Surgery, Division of General Surgery, McMaster University, Hamilton, Ontario, Canada.
  • Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada.
  • Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • NYU Langone Health, New York University, New York, New York, USA.
  • Department of Medicine, Division of Infectious Diseases, McMaster University, Hamilton, Ontario, Canada.

Zitieren

APA

Park, L. J., D'Souza, D., Kazi, T., Rodriguez, F., Griffiths, C., McKechnie, T., Mertz, D., & Serrano, P. E. (2024). Comparing cefazolin/metronidazole, piperacillin‐tazobactam, or cefoxitin as surgical antibiotic prophylaxis in patients undergoing pancreaticoduodenectomy: A retrospective cohort study. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27641

Vancouver

Park LJ, D'Souza D, Kazi T, Rodriguez F, Griffiths C, McKechnie T, et al. Comparing cefazolin/metronidazole, piperacillin‐tazobactam, or cefoxitin as surgical antibiotic prophylaxis in patients undergoing pancreaticoduodenectomy: A retrospective cohort study. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27641

BibTeX
@article{Park2024,
  author = {Park, Lily J and D'Souza, Daniel and Kazi, Tania and Rodriguez, Felipe and Griffiths, Christopher and McKechnie, Tyler and Mertz, Dominik and Serrano, Pablo E},
  title = {Comparing cefazolin/metronidazole, piperacillin‐tazobactam, or cefoxitin as surgical antibiotic prophylaxis in patients undergoing pancreaticoduodenectomy: A retrospective cohort study},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1002/jso.27641}
}
Kostenlos starten →